Author: Okorie Okorocha, J.D., M.S., M.S.

Attorney, forensic toxicologist, and expert witness working at the intersection of law, pharmacology, toxicology, drug and alcohol evidence, and complex scientific evidence.

The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Total and Unbound Drug Concentrations: What a Fasting Study Could Not Resolve

A laboratory can quantify total drug in plasma while struggling to quantify the much smaller unbound portion. That difference can determine whether a pharmacokinetic study answers its question. A result reported as not statistically significant does not resolve the question when the measurements are too limited to detect a meaningful…

Read Article: Total and Unbound Drug Concentrations: What a Fasting Study Could Not Resolve

Midazolam Sedation Models: Why a Medication Association Does Not Prove Antagonism

A medication can be associated with a different drug response because of the condition it was prescribed to treat. That possibility matters when interpreting a concentration-response model as evidence of a pharmacodynamic interaction. Franken and colleagues examined this problem in a study of midazolam sedation in terminally ill adults. Their…

Read Article: Midazolam Sedation Models: Why a Medication Association Does Not Prove Antagonism

CBD After Repeated Dosing: Why Detectability Does Not Establish a Washout Deadline

A cannabinoid detected after dosing stops is evidence of analytical persistence. It does not, by itself, establish an exact elimination half-life, the time of the last dose or a universal date when another person’s sample will test negative. A controlled study by Wolinsky and colleagues helps explain the distinction. Published…

Read Article: CBD After Repeated Dosing: Why Detectability Does Not Establish a Washout Deadline